Signs of slowing down ,
Some offloading in the recent past
Q1FY23 Concall (Just scribble will post the detailed one once the transcript is released )
Revenue impact
- US 4% grown QOQ and degrown 4% YOY
- 10% of the Revenue is Profit share ( I think this related to in-license products I guess )
- Supply Chain Issues (Syringe Issues ) : 25 crores lost Developed Markets || 40 crores lost in Indian Market || 100 crores lost ROW markets
- Syringe Issues mitigation Plans : Some other suppliers (syringes) we are qualifying from the china and Italy for the rest of the world This is easy to do in India but takes some time in regulated markets
- Shutdown of the insulin lines
- India market down from 200 crores to 50 crores (Intentionally let the business go due to low margins , this was supplying to third parties )
- Capex In-line with last year
- Biologics CDMO
- 4 customer visits happened
- Discussing about commercial terms with the potential customers
- No clarity yet on when revenue contribution from this segment
- Is there any CDMO opportunity from Henlius ?
- China : Two molecules got exception from inspections (might commercialize by this or next quarter ) 4 filings in FY23 and 6-7 in FY24